Skip to main content

News
& Events

Events

February 12, 2024

SMFM 2024 Pregnancy Meeting – Championing Maternal Health: Nobel Prize-Winning Discoveries Transforming Preeclampsia

Learn More

October 10, 2023

XXIV FIGO World Congress – Championing Maternal Health: Nobel Prize-Winning Discoveries Transforming Preeclampsia

Learn More

Press Releases

January 17, 2024

Comanche Biopharma Closes Oversubscribed $75 Million Series B Financing to Advance Mission to Develop and Make Globally Available the First Treatment Targeting a Root Cause of Preeclampsia

August 28, 2023

Comanche Biopharma Named by Fierce Biotech as a “Fierce 15” Biotech Company of 2023

August 23, 2023

Comanche Biopharma Receives US FDA Fast Track Designation for CBP-4888 for the Treatment of sFlt-1 mediated pre-term preeclampsia

June 13, 2023

Comanche Biopharma Strengthens Board of Directors with Appointment of Dr. Ann Taylor

May 12, 2023

Comanche Biopharma Appoints Allyson Felix to Board of Directors

March 30, 2023

Comanche Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for CBP-4888, an siRNA Investigational Therapy for the Treatment of Preeclampsia

December 15, 2022

Comanche Biopharma Announces Appointment of Allison August, M.D., as Chief Medical Officer

Media Contact

Liz Melone
Melone Communications, LLC
Mobile: +1 617-256-6622
Email: press@comanchebiopharma.com

Contact Us

50 Beharrell St, Unit B
Concord, MA 01742

Contact Us

Comanche is a biopharmaceutical company developing a novel siRNA therapy for the treatment of preeclampsia. Our purpose is to lower the risks of pregnancy and prematurity worldwide by safely sustaining pregnancy. We envision a world where all pregnant women have access to safe and effective therapies that are evidence-based, cost-effective and sustainable.

Sign up to receive email updates

Translate 🌎 💬